Academic Highlights: New Developments in the Treatment of Schizophrenia. [CME]
J Clin Psychiatry 2007;68(3):463-478
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Schizophrenia is a disease that ranks in the top 5 causes of disability for young adults in developed countries.1 In addition to the delusions, hallucinations, and disturbances in affect that are characteristics of schizophrenia, the illness is also associated with impairments in the high-level functions of planning, learning, and social activity. The impairments of schizophrenia impact every aspect of a patient’s life and thereby have a debilitating effect on the patient’s ability to function in society.